Oncology,Weekly Roundups,Biology

Weekly News Round-up – 17/1/20

Proventa International Weekly News 3 years ago By admin

The week passed fairly uneventfully this time, with the baffling politics and shocking events of the new decade struggling to get started. Instead, research from Scottish universities indicated a link between a type of common gut bacteria and Parkinson’s; a heart disease-related treatment from AstraZeneca has folded, costing them potentially $100 million; and the NHS has struck a “landmark” deal with Novartis to trial a new statin type for five years.

NEW RESEARCH ON PARKINSON’S AND GUT BACTERIA LINKS – Research from the Universities of Edinburgh and Dundee has found that the common bacteria bacillus subtilis which boosts digestive health can slow or reverse the build-up of the alpha-synuclein protein, commonly linked with Parkinson’s. In the study, researchers altered roundworms to produce the human form of alpha-synuclein and fed probiotics to see what affected the toxic build-up. Bacillus subtilis not only prevented but also cleared some of the protein build-up, improving movement symptoms and preventing toxic formations by producing new chemicals to alter how the cell enzymes worked. The test will now be confirmed in mouse models. 

ASTRAZENECA LOSES $100 MILLION IN FAILED HEART DRUG TRIALS – AstraZeneca is set to lose $100 million after its fish oil tablet Epanova was found not to treat mixed dyslipidaemia, a condition linked to heart disease which causes raised levels of cholesterol in the blood, and was discontinued. 

In other news: 

R&D
15-year Roche-Illumina genomics alliance struck to focus on cancer

Clinical Trials
NHS strikes landmark five-year statin trial deal with Novartis
BMS’ first-line NSCLC combo granted FDA fast review

Manufacturing
Biogen buys experimental Alzheimer’s and Parkinson’s treatment from Pfizer
Eli Lilly partners with Strateos on California robotic laboratory

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

More news

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies

Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...

2 years ago
Oncology,Weekly Roundups,Biology

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies

Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...

2 years ago

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago
Oncology,Weekly Roundups,Biology

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago

Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets

Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...

2 years ago
Oncology,Weekly Roundups,Biology

Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets

Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...

2 years ago